# Earendil Labs

**Source:** https://geo.sig.ai/brands/earendil-labs  
**Vertical:** BioTech  
**Subcategory:** AI Drug Discovery  
**Tier:** Challenger  
**Website:** earendil.bio  
**Last Updated:** 2026-04-14

## Summary

Full-stack AI biologics company raised $787M in Mar 2026 backed by Sanofi, Pfizer/Hillhouse, and DST Global; $2.56B Sanofi collaboration signed Jan 2026; platform generates 40+ AI-designed protein therapeutics across multiple therapeutic areas.

## Company Overview

Earendil Labs is a full-stack AI biologics company that uses a proprietary AI platform to design protein therapeutics at scale. The company secured $787 million in financing in March 2026, backed by Sanofi, the Pfizer-Hillhouse Biotech Fund, Dimension Capital, and DST Global — one of the largest AI drug discovery raises in the industry's history.

The scale of Sanofi's involvement underscores Earendil's platform credibility: the companies signed a $2.56 billion collaboration agreement in January 2026, under which Sanofi gains access to Earendil's AI-generated biologics pipeline across multiple therapeutic areas. The partnership was followed by the broader financing round just weeks later, with Pfizer and DST providing additional validation from both strategic and growth-investment perspectives.

Earendil's AI platform has generated over 40 drug programs, with a Phase 2-ready asset for inflammatory bowel disease among its most advanced candidates. The company is positioning itself as a new model for pharmaceutical R&D — one where AI can generate, screen, and optimize biologics programs in silico before any wet lab work, compressing timelines and reducing the capital intensity of early-stage drug discovery.

## Frequently Asked Questions

### What does Earendil Labs do?
Full-stack AI biologics company — uses AI to design protein therapeutics at scale, generating drug programs in silico before wet lab validation.

### How much has Earendil raised?
$787M in financing (March 2026), backed by Sanofi, Pfizer/Hillhouse Biotech Fund, Dimension Capital, and DST Global.

### What is the Sanofi collaboration?
A $2.56B collaboration signed January 2026, giving Sanofi access to Earendil's AI-generated biologics pipeline across multiple therapeutic areas.

### How many programs has Earendil's AI generated?
40+ drug programs, including a Phase 2-ready asset for inflammatory bowel disease.

### What is Earendil Labs' AI drug discovery approach?
Earendil Labs uses generative AI models trained on protein structure, bioactivity, and ADMET (absorption, distribution, metabolism, excretion, toxicity) data to design novel drug-like molecules with predicted activity against validated targets. The system iterates through design-predict-synthesize cycles, using computational prediction to prioritize which molecules are worth physically synthesizing and testing, dramatically reducing the experimental burden of lead optimization.

### What therapeutic areas does Earendil Labs focus on?
Earendil Labs focuses on targets in oncology and immunology where protein structure-based design has shown strong results (kinase inhibitors, protein-protein interaction disruptors) and where the Sanofi collaboration provides resources and expertise. The company selects targets that are computationally tractable — well-characterized binding sites, existing structural data — where AI-guided design can deliver meaningful speed advantages over traditional medicinal chemistry.

### What are the details of the Sanofi collaboration?
Earendil Labs announced a research collaboration with Sanofi providing funding and access to Sanofi's biological expertise and clinical development infrastructure in exchange for rights to drug candidates emerging from the collaboration. Such pharma-AI collaboration structures typically include upfront research payments, milestone payments tied to drug candidate nomination and clinical progression, and royalties on commercialized drugs. The Sanofi partnership validates Earendil's platform and provides a non-dilutive funding stream.

### How many programs has Earendil's AI generated and what does this demonstrate?
Earendil Labs has used its AI platform to generate multiple drug candidate programs across different targets, demonstrating platform breadth and productivity. High program generation throughput is a key metric for AI drug discovery companies — it demonstrates that the AI doesn't just work for one target but generalizes across the chemical and biological diversity of different drug discovery projects. Investors and pharma partners evaluate program generation velocity as a proxy for platform capability.

## Tags

healthtech, b2b

---
*Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*